Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 10/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 8/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28010069 | 0.80 | POLB (0.65) | HDAC6POLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL1040774 | 0.80 | HDAC6 (0.68) | HDAC6POLBSLC6A4SMN1; SMN2MAPT | |
| SCHEMBL29353516 | 0.80 | HDAC6 (0.68) | HDAC6POLBSLC6A4SMN1; SMN2MAPT | |
| SCHEMBL5476110 | 0.73 | MEN1 (0.54) | HDAC6SLC6A4SMN1; SMN2MAPTGAA | |
| SCHEMBL29351335 | 0.70 | HDAC6 (1.00) | HDAC6POLBSLC6A4SMN1; SMN2MAPT | |
| SCHEMBL1424836 | 0.70 | HDAC6 (1.00) | HDAC6POLBSLC6A4SMN1; SMN2MAPT | |
| SCHEMBL811058 | 0.69 | HDAC6 (0.53) | HDAC6SMN1; SMN2MAPTGAAKMT2A | |
| SCHEMBL8378911 | 0.69 | POLB (0.71) | HDAC6POLBSLC6A4SLC6A2SLC6A3 | |
| SCHEMBL31645023 | 0.69 | POLB (0.43) | POLBSLC6A4SLC6A2SLC6A3SMN1; SMN2 | |
| SCHEMBL31645083 | 0.69 | POLB (0.43) | POLBSLC6A4SLC6A2SLC6A3SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7176320-B2 | Benzimidazole derivative | TEIJIN LIMITED (JP) | 2007-02-13 | — | — | US | disclosed |
| US-20050267148-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2005-12-01 | — | — | US | disclosed |
| US-20040162311-A1 | Benzimidazole derivative | TEIJIN LIMITED | 2004-08-19 | — | — | US | disclosed |
| US-20040010004-A1 | Benzimidazole derivatives | TEIJIN LIMITED (JP) | 2004-01-15 | — | — | US | disclosed |
| EP-1249450-A1 | BENZIMIDAZOLE DERIVATIVES | TEIJIN LIMITED (JP) | 2002-10-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040162311-A1 | Benzimidazole derivative | CMA1, CBR3, CBR1 | HDAC6 87/4885POLB 2733/4885SLC6A4 1932/4885 |
| US-20040010004-A1 | Benzimidazole derivatives | CMA1, CBR3, CBR1 | HDAC6 83/4885POLB 2792/4885SLC6A4 1888/4885 |
| US-20050267148-A1 | Benzimidazole derivative | CMA1, SERPINB1, TPSAB1 | HDAC6 89/4885POLB 2302/4885SLC6A4 1230/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.